Towa Expects To Grow By Over A Third With Pensa
Sees 5% Annual Increase On The Back Of New Launches
Towa says it expects consolidating the Pensa business it acquired earlier this year to boost its sales by more than a third in its current financial year. Meanwhile, the Japanese firm has reported sales ahead by 5% in the year ended March 2020 on the back of new launches, as well as growth in profits despite local price cuts.
You may also be interested in...
Japan’s Towa has almost achieved its full-year operating profit goal in the first nine months of its financial year thanks to lower costs.
Japan’s Towa has completed its €329m deal for the Pensa Investments generics business of Spain’s Esteve.
While the AAM is lobbying for a renewed focus on domestic drug production amid fresh concerns about the globalization of the US pharmaceutical drug supply chain, the association has urged US Congress to have confidence in FDA oversight, insisting that “the US has one of the safest drug supply chains in the world.”